ストックスクリーナーアプリを入手
3.31
5.08%
0.16
プレマーケット:
3.38
0.07
+2.11%
前日終値:
$3.15
開ける：
$3.24
24時間の取引高:
427.81K
Relative Volume:
0.68
時価総額：
$76.95M
収益：
-
当期純損益:
$-29.25M
株価収益率:
-2.7909
EPS:
-1.186
ネットキャッシュフロー:
$-22.80M
1週間 パフォーマンス:
+38.49%
1か月 パフォーマンス:
-10.78%
6か月 パフォーマンス:
-44.74%
1年 パフォーマンス:
-18.47%
1日の値動き範囲:
$3.03
$3.355
1週間の範囲:
$2.355
$3.355
52週間の値動き範囲:
$1.73
$7.38
Sagimet Biosciences Inc Stock (SGMT) Company Profile
名前
Sagimet Biosciences Inc
セクター
電話
(650) 561-8600
住所
155 BOVET RD., SUITE 303, SAN MATEO
SGMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
3.31 | 76.95M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | Oppenheimer | Outperform |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-06-28 | ダウングレード | Goldman | Buy → Neutral |
| 2024-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-25 | 開始されました | Leerink Partners | Outperform |
| 2023-08-08 | 開始されました | Goldman | Buy |
| 2023-08-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-08 | 開始されました | Piper Sandler | Overweight |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
すべてを表示
Sagimet Biosciences Inc (SGMT) 最新ニュース
Insider’s View: Deciphering Sagimet Biosciences Inc (SGMT)’s Financial Health Through Ratios - DWinneX
Sagimet Biosciences Inc [SGMT] Shares Rise 8.82 % on Wednesday - knoxdaily.com
What is Sagimet Biosciences Inc (SGMT) Stock Return on Shareholders’ Capital? - Sete News
Sagimet Biosciences (SGMT) to Present Denifanstat Study Findings at EASL 2025 | SGMT Stock News - GuruFocus
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 - GlobeNewswire
Breakthrough MASH Drug Shows Extended Phase 2b Results: 3 New Analyses Reveal Treatment Impact - Stock Titan
Sagimet Biosciences Inc (SGMT) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Predicting Sagimet Biosciences Inc’s (SGMT) earnings for the current quarter - uspostnews.com
20,103 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by American Century Companies Inc. - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Holdings of Sagimet Biosciences Inc (SGMT) are aligned with the stars - Sete News
SGMT’s Debt-to-Equity Ratio at 0.00: What It Means for Sagimet Biosciences Inc’s Future - investchronicle.com
Virtu Financial LLC Sells 9,123 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - The AM Reporter
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus Price Target from Analysts - Defense World
HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World
Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks
HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks
Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet’s FASN inhibitor cleared to enter clinic for acne - BioWorld MedTech
Sagimet Biosciences Inc. (SGMT) reports earnings - Quartz
Sagimet Biosciences Inc. SEC 10-K Report - TradingView
Sagimet's FDA Breakthrough Drug Enters Phase 3 Trials with $158M War Chest - StockTitan
Promising Developments in Sagimet Biosciences: IND Clearance for TVB-3567 and Ongoing Success of Denifanstat - TipRanks
Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567 - TipRanks
Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials -March 11, 2025 at 10:46 am EDT - Marketscreener.com
Sagimet Biosciences receives FDA nod to begin testing its therapy for acne -March 11, 2025 at 09:38 am EDT - Marketscreener.com
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - SEC.gov
Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567 - TipRanks
Sagimet Biosciences Announces Clearance of IND for FASN - GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for ... - The Bakersfield Californian
FDA Clears Groundbreaking Acne Drug: Sagimet's New FASN Inhibitor Targets 50M Patient Market - StockTitan
Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha
Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Insider Monkey
10 Best Get Rich Quick Stocks To Invest In - Insider Monkey
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World
10 Hot Penny Stocks to Buy Now - Insider Monkey
Unveiling Hidden Gems: The Hot Penny Stock You Might Be Missing - Reporteros del Sur -
Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now - Insider Monkey
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
🛡️ When is it a good time to purchase SGMT? - AInvest
Sagimet Biosciences Announces Oral Presentation at the MASH - GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic ... - The Bakersfield Californian
Could This New MASH Drug Transform Liver Disease Treatment? Key Phase 2b Results Revealed - StockTitan
FY2024 Earnings Estimate for SGMT Issued By Leerink Partnrs - MarketBeat
Technical analysis of Sagimet Biosciences Inc (SGMT) stock chart patterns - US Post News
FY2024 Earnings Forecast for SGMT Issued By Leerink Partnrs - Defense World
Sagimet Biosciences Inc (SGMT) 財務データ
収益
当期純利益
現金流量
EPS
0.19%
大文字化:
|
ボリューム (24 時間):